Optimize Opdivo Denial Management with Klivira Automation

The Impact of Opdivo Denials on Your Revenue Cycle

Denials for high-volume, high-cost therapies like Opdivo directly impact cash flow and patient care continuity. Manual denial resolution, involving staff parsing X12 835 remittance advice or X12 277 claim status, can lead to significant rework costs and staff time allocation, as highlighted by industry benchmarks like the CAQH Index and MGMA surveys. Each unaddressed or delayed Opdivo denial represents a potential write-off that could have been overturned with an efficient appeal.

Common Denial Triggers for Opdivo

• Clinical necessity not adequately documented per payer policy or NCCN guidelines.
• Failure to meet step-therapy requirements or obtain formulary exceptions.
• Missing or incomplete biomarker testing results (e.g., PD-L1 status).
• Technical denials such as missing modifiers, eligibility mismatches, or incorrect CPT codes.
• Insufficient evidence for off-label indications, requiring robust peer-reviewed literature.
• Timely filing breaches for initial claims or subsequent appeals.

Klivira's Automated Workflow for Opdivo Denial Management

Klivira's platform ingests Opdivo denials from all channels, including X12 835 transactions, X12 277 claim status, payer portals, and Da Vinci PAS ClaimResponse messages. Our system then normalizes X12 CARC/RARC codes and payer-specific local variations into a uniform reason set. This enables auto-routing of Opdivo denials to the appropriate pathway: claim correction, appeal, peer-to-peer review, or write-off, ensuring no appealable denial is overlooked due to manual capacity constraints.

Precision Appeal Packet Assembly for Opdivo

For clinical-necessity denials related to Opdivo, Klivira automates the assembly of comprehensive appeal packets. Our FHIR-enabled EMR integration pulls critical clinical documentation such as progress notes, pathology reports (including PD-L1 status), prior-line therapy history, and imaging results. This ensures that every Opdivo appeal is submitted with the strongest available supporting documentation, aligned with payer-specific appeal-pathway requirements and clinical guidelines.

Key Automation Benefits for Opdivo Appeals

• Eliminate CARC/RARC parsing errors with normalized denial taxonomies.
• Prevent timely-filing breaches through automated tracking and proactive deadline surfacing.
• Reduce lost-to-follow-up appeals with continuous status monitoring.
• Strengthen appeal packets with automated, comprehensive documentation discovery via FHIR.
• Ensure correct appeal level invocation based on payer-specific logic.
• Identify and overturn appeals that would have been written off due to manual capacity.

Integrating Denial Insights for Upstream Prior Authorization

Klivira's platform goes beyond reactive denial management by providing actionable insights. Our reporting and pattern detection capabilities surface common Opdivo denial reasons by payer, service line, and provider. This feedback loop informs upstream prior authorization submission improvements, helping your team refine initial PA requests for Opdivo and similar oncology drugs, ultimately reducing future denials and improving first-pass approval rates.